Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 3Completed 2Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3Lymphoid 1

Conditions

Pancreatic Neoplasms 56Biliary Tract Neoplasms 24Cholangiocarcinoma 23Nasopharyngeal Carcinoma 22Carcinoma, Non-Small-Cell Lung 22Urinary Bladder Neoplasms 18Breast Neoplasms 18Neoplasm Metastasis 17Lung Neoplasms 14Lymphoma, Large B-Cell, Diffuse 13Colorectal Neoplasms 12Carcinoma, Transitional Cell 12Recurrence 9Non-Muscle Invasive Bladder Neoplasms 9Sarcoma 8Ovarian Neoplasms 8Triple Negative Breast Neoplasms 7Neoplasms 7Gallbladder Neoplasms 7Hodgkin Disease 6Nasopharyngeal Neoplasms 5Bile Duct Neoplasms 5Adenocarcinoma 5Uterine Cervical Neoplasms 4Locally Advanced Pancreatic Cancer 4Endometrial Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Adenocarcinoma 3Osteosarcoma 3Lymphoma, T-Cell, Peripheral 3

Interventions

Injections 12pembrolizumab 7toripalimab 6tislelizumab 5Oxaliplatin 3Gemcitabine 3Cisplatin 3Carboplatin 3trastuzumab deruxtecan 2spartalizumab 2lenvatinib 2atezolizumab 2Paclitaxel 2Nivolumab 2Immune Checkpoint Inhibitors 2Fulvestrant 2Fluorouracil 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Bevacizumab 2Albumin-Bound Paclitaxel 2zimberelimab 1penpulimab 1olaparib 1niraparib 1nedaplatin 1fludarabine phosphate 1fludarabine 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Advanced Solid Tumor × Gemcitabine × Clear all
NCT05279300 2025-08-11

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

CStone Pharmaceuticals

Phase 1 Recruiting
480 enrolled
LymphoidOther solid neoplasm

Advanced Solid Tumor

NCT06139211 2024-12-20

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Recruiting
186 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05525247 2023-09-21

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

Selecxine

Phase 1/2 Recruiting
420 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡